TCRT
NASD Alaunos Therapeutics, Inc.$0.9605 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.9605, $0.0868 below the day’s high of $1.0473
- YTD change
- -70.26%
- vs 20-day SMA
- -32.38%
- vs 200-day SMA
- -62.18%
Price ranges
Price & Performance
-1.86 (-65.94%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.8% away from all-time highs of $601.5000
- TCRT is down 70% since the beginning of the year
- TCRT is down 61% over the past 12 months
- TCRT is down 40% over the past 1 month
- 0% of all TCRT investors are betting against TCRT
TCRT reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -61.5%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0100
- Last 5 days
- -23.77%
- vs 8-day SMA
- -20.95%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
